The DxBooks team is excited to announce the launch of the refreshed 2023 NGS Oncology DxBook. The NGS Oncology DxBook serves as a lab-level view of the clinical NGS market for therapy selection. The first edition of the NGS Oncology DxBook featured comprehensive in-house workflow coverage of 70 institutions in the US. This year, in addition to refreshing the data collected last year to capture trends over time, we are also:

1. Expanding our coverage to over 100 U.S. institutions and to top European geographies (France, Germany, Italy, Spain, and the UK)
2. Including labs that currently only send out NGS testing to understand decentralization and inquire about future adoption
3. Increasing the breadth and depth of in-house panel coverage
4. Capturing future trends including the impact of the VALID Act and plans for adopting additional lab infrastructure
5. Identifying customers’ most important criteria for adopting sequencing platforms, liquid handler/sample prep instruments, and bioinformatics pipelines
6. And much more!  

The NGS Oncology DxBook can be used by strategy, product, sales, marketing, and business development professionals in the NGS industry. DxBooks data provides unparalleled granularity and insight for numerous use cases, including:

1. Monitoring shifts in the NGS oncology market
     a. Are labs shifting from small solid tumor panels to large solid tumor panels?
    b. Are labs adopting newer low-cost platforms?
2. Product development
     a. Which biomarkers are most frequently requested by clinicians in Solid Tumor Panels?
     b. What features of instruments/software are lab directors most interested in?
3. Competitive intelligence/benchmarking
     a. Which panels are your products being used for?
4. Proactive targeted sales
     a. Which labs are looking to adopt new instruments/software and are looking for qualities our product offers?
5. Identify partnerships
     a. Are your products often used alongside another company’s products?

Data collection for the 2023 NGS Oncology DxBook is already well underway with great success, and our Q1 data delivery is available now with granular data on 50 institutions. Stay tuned as we share additional periodic insights from our database! To learn more about the NGS Oncology DxBook or to request a demo, please contact us at dxbooks@decibio.com.